Patents Assigned to ANTECIP BIOVENTURES II LLC
  • Bupropion as a modulator of drug activity
    Patent number: 10874665
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10874663
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: December 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10864209
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: December 15, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion and dextromethorphan for treating nicotine addiction
    Patent number: 10813924
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: October 27, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10806710
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 20, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Combination of dextromethorphan and bupropion for treating depression
    Patent number: 10799497
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 13, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10786469
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: September 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10786496
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: September 29, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10780064
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: September 22, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10780066
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: September 22, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10772850
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: September 15, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion and dextromethorphan for treating nicotine addiction
    Patent number: 10688066
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: June 23, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
    Patent number: 10596167
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 24, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10548857
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 4, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10512643
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 24, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
    Patent number: 10493085
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: December 3, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
    Patent number: 10463682
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid form or a salt form, such as a disodium salt form, can be used to treat or alleviate pain or related conditions, such as low back pain.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: November 5, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10463634
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 5, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10420782
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 24, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10413560
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 17, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau